Editas Medicine has shared early clinical data on the cell therapy it is developing to challenge Vertex and CRISPR Therapeutics for the sickle cell market. The CRISPR-edited therapy showed clear signs of efficacy but, with its rivals awaiting FDA approval, differentiating a late-to-market challenger could be tough.